The American Journal of Managed Care29d
Advancing CLL and MCL Care: The Impact of BTK Inhibitors in Treatment-Naive Patients and Emerging Therapies
Panelists discuss how, coming into ASH 2024, the largest unmet needs in the treatment and management of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) include improving outcomes ...
The American Journal of Managed Care23d
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations. Today we ...